Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Brexit, UK Regulator Remains Pharma Favorite – For Now

Executive Summary

The European medicines regulatory network is planning for a worst-case scenario and is advising drug companies to do the same to ensure there are no last-minute disruptions when the UK leaves the EU at the end of March 2019. It appears this advice has yet to have an effect on the industry’s preference for the UK to lead the evaluation of human medicines under the decentralized procedure. The Pink Sheet‘s Vibha Sharma spoke to two senior national regulators to find out how the network is coping with the situation.

Related Content

Topics

UsernamePublicRestriction

Register

PS121032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel